platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds that broaden the Company’s product pipeline.
AsiDNA™, the first compound sourced from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy mechanism with an agonist effect, acting upstream of multiple DDR pathways. AsiDNA™ has the ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy, radiotherapy and PARP inhibitors. Thanks to a good safety profile, AsiDNA™ is particularly amenable to combination treatment, a standard of care in aggressive or resistant cancers. AsiDNA™ is currently evaluated in a phase 1b study in combination with chemotherapy and its clinical evaluation in combination with PARP inhibitors is expected to start shortly.
OX401 is the second drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance.
Onxeo’s portfolio also includes belinostat, a HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq® (belinostat IV form). Acrotech BioPharma LLC, a subsidiary of Aurobindo Pharma, has exclusive rights to belinostat.
Last updated on